{
    "nctId": "NCT04809779",
    "briefTitle": "PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC",
    "officialTitle": "PD-1 Inhibitor Sintilimab Concurrent With Epirubicin Cyclophosphamide and Nab-paclitaxel as Neoadjuvant Therapy for Triple Negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Pathologic Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed histologically confirmed stage I-III, ER, PR and HER2 negative invasive breast cancer as defined by the ASCO CAP guidelines for whom systemic chemotherapy would be indicated based on physician judgment following standard NCCN practice guidelines.\n\nExclusion Criteria:\n\n* Patients for whom anthracycline, nab-paclitaxel or antibody therapies are contraindicated.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}